Assertio Holdings, Inc. (NASDAQ: ASRT)

Assertio Holdings, Inc., a commercial pharmaceutical company, specializes in the development and marketing of differentiated products to patients. The company, which trades under the symbols ASRT and ASRTW, was founded in 2014 and is headquartered in Deerfield, Illinois. Assertio's primary marketed products include ROLVEDON, INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor.

Assertio operates in the pharmaceutical industry, with its main business activities revolving around the development and marketing of its diverse range of products. These activities span across several countries, including the United States, Canada, Italy, and South Korea, where the company's products are manufactured at contract manufacturing facilities. Assertio is responsible for the supply and distribution of its marketed products.

The company generates revenue through the sales of its primary products and services. ROLVEDON, a long-acting granulocyte colony-stimulating factor (G-CSF), is used to decrease the incidence of infection in adult patients with nonmyeloid malignancies. INDOCIN, a nonsteroidal anti-inflammatory drug (NSAID), is used to treat various conditions such as rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, and acute gouty arthritis. Sympazan, a benzodiazepine, is used to treat seizures associated with Lennox-Gastaut Syndrome (LGS) in patients aged two years or older. Otrexup, a folate analog metabolic inhibitor, is used to manage severe, active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis. SPRIX, a non-narcotic nasal spray, is used to manage moderate to moderately severe pain that requires analgesia at an opioid level. CAMBIA and Zipsor, both prescription NSAIDs, are used to treat acute migraine attacks and mild to moderate pain in adults, respectively.

Assertio holds a strong position within the industry, with its key competitors including pharmaceutical and biotechnology companies, generic drug companies, and medical devices and drug delivery companies. The company's competitive advantages lie in its strong commercial organization, which includes a sales force, a non-personal promotion model, and market access programs.

The company's customer base primarily consists of healthcare providers and institutions, as well as patients with the conditions that the company's products treat. However, specific names of customers are not provided in the document.

Assertio's product portfolio includes patents and proprietary rights covering its products and technologies. The company's intellectual property portfolio provides a significant competitive advantage, as it protects the company's products and technologies from competitors.

In terms of brand names, Assertio's primary products include ROLVEDON, INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. These brands are well-known within the pharmaceutical industry and are recognized for their effectiveness in treating various conditions.